

# ABOUT ' AGENDA ' DAY TWO DAY ONE DAY TWO

Download the Brochure



# Day One

Tuesday - March 31, 2020

# **Day Two**

Wednesday - April 1, 2020

8:30 am Coffee & Networking

8:55 am Chair's Opening Remarks

Holger Wesche

CSO, Harpoon Therapeutics Inc.

Analyzing Tumor Target Selection to Maximize Efficacy Whilst Minimizing Toxicity

9:00 am Multi-functional Antibody-based Immunotherapies Enabling Precision Targeting of Tumor Cells and Transformation of the Local Immunological Environment

Andreas Loew

President & CEO, Elstar Therapeutics

9:30 am Protease Dependent COBRATM Activity Regresses Established Tumors in Mice

Chad May

Senior Vice President - Research & Development, Maverick Therapeutics

10:00 am Analyzing Tumor Target Selection to Maximize Efficacy Whilst Minimizing Toxicity

Alison Betts

Sr. Director of Scientific Collaborations and Fellow of Modeling & Simulation, Applied Biomath

### Optimizing Next Generation Drug Discovery through Advances in Technology

10:30 am Optimizing Next-Generation Drug Discovery through Advances in Technology

Paul Moore

VP, Cell Biology and Immunology, MacroGenics

11:00 am A Novel Class of Antibodies to Enhance CD3 Bispecific Activity in Solid Tumors

Jessica Kirshner

Senior Director of Oncology, Regeneron Pharmaceuticals

11:30 am Morning Refreshments

12:00 pm A T Cell-Engaging Antibody for Treatment of FLT3-expressing Leukemias

Jennifer Michaelson

Chief Development Officer, Biologics, Cullinan Oncology

12:30 pm Networking Lunch

Analyzing the Biology of T cells, NK cells & the Tumor Microenvironment to Improve Cell Engager **Therapies** 

1:30 pm IL-15 Containing Trispecific Killer Engagers (TriKETM) To Make NK Cells Antigen Specific

Jeffrey Miller

, University of Minnesota

2:00 pm Comparing the Biology of Conditional Agonists Targeting CD3, the g9d2 TCR and NK

**Activation Receptors** 

Brian Rabinovich

Director, EMD Serono

2:30 pm Opening up the Tumor Microenvironment to Enable T cell Directed Therapies and more

Tatiana Novobrantseva

Co-founder & CSO, Verseau

3:00 pm Afternoon Refreshments & Networking

3:30 pm Bispecific γδ-T cell Engagers for Cancer Immunotherapy

Hans van der Vliet

CSO/CMO, Lava Therapeutics

## Comparing Cell Engagers with CAR Therapeutics and Bispecifics

4:00 pm Benchmarking T Cell-Redirecting Therapies for Cancer: Comparing CD3Bispecifics and CAR T Cells

David DiLillo

Associate Director, Immuno-Oncology, Regeneron

4:30 pm Design Strategies and Insights on the Activity of Cell Engagers with CAR Therapeutics and Bispecifics

Rajkumar Ganesan

Director of Bispecific Antibodies & CAR-T, Janssen

5:00 pm Chair's Closing Remarks & Close

Omid Vafa

CBO, TeneoBio

NEXT PAGE: DAY ONE CLICK HERE >









OUR CONTACT DETAILS

T: (+1) 617 455 4188

E: info@hansonwade.com

**VENUE DETAILS** 


**Boston, MA** 

#### **ABOUT US**

Hanson Wade's goal is to accelerate progress within organisations and across industries. Our primary method for achieving this is by creating exclusive business conferences that gather together the world's smartest thinkers and doers.

#### **LOCATION**

Grotere kaart weergeven



© Copyright 2018 Hanson Wade | Design and site by Event Engine | Hanson Wade Limited is registered in England & Wales, number 06752216.

Registered Office: Suite A, 6 Honduras Street, London EC1Y 0TH.

**Terms & Conditions** 

**Privacy Policy**